Conclusion: ISL/DOR-based regimens maintained viral suppression through week 96. ISL/DOR regimens were well tolerated regardless of dose.
Highlights of Presecribing Information: Trogarzo
Highlights of Presecribing Information: Trogarzo Read More »
Cabotegravir, discovered concurrently with dolutegravir,39 has a very long human half-life and is being investigated clinically as a long acting injectable in combination with the NNRTI rilpivirine
UNAIDS commentary regarding the announcement of the U.S. Food and Drug Administration’s approval of Apretude
News article announcing the U.S. Food and Drug Administration’s approval of Apretude
FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention Read More »
